[6R]-MTHF-EFFECTIVE FOLATE ALTERNATIVE IN CHEMOTHERAPY BASED ON 5-FLUOROURACIL Russian patent published in 2022 - IPC A61K31/4745 A61K31/513 A61K31/519 A61K39/00 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention relates to the use of [6R]-5,10-methylenetetrahydrofolate for the treatment of colorectal cancer in humans, where the treatment includes following stages: a) on day 1, injection of an intravenous bolus containing 5-FU (5-fluorouracil) in the amount of 300-500 mg/m² of BSA (body surface area), followed by b) injection of one intravenous bolus containing 30-240 mg/m² of [6R]-5,10-methylenetetrahydrofolate after a period of approximately 30 min, or c) injection of 30-240 mg/m² of [6R]-5,10-methylenetetrahydrofolate by two intravenous boluses distributed approximately 30 and 60 min after the bolus injection of 5-FU, followed by d) on day 2, injection of an intravenous bolus containing 5-FU in the amount of 300-500 mg/m² of BSA, in 30 min followed by e) injection of one intravenous bolus containing [6R]-5,10-methylenetetrahydrofolate in the amount of 30-240 mg/m² of BSA, where the stage (b) may be repeated up to 4 times a day 1 with an interval of 10-60 min between injections of each bolus, and where the stage (d) is possibly repeated up to 4 times a day 2 with an interval of 10-60 min between injections of each bolus, and where all stages (a)-(e) are possibly repeated every 2 weeks up to eight (8) cycles, that is, up to sixteen (16) weeks.

EFFECT: obtaining a drug for the treatment of colorectal cancer.

12 cl, 3 dwg, 1 tbl, 1 ex